The role of latency reversal in HIV cure strategies

One strategy to eliminate latently infected cells that persist in people with HIV on antiretroviral therapy is to activate virus transcription and virus production to induce virus or immune‐mediated cell death. This is called latency reversal. Despite clear activity of multiple latency reversal agen...

Full description

Saved in:
Bibliographic Details
Published inJournal of medical primatology Vol. 51; no. 5; pp. 278 - 283
Main Authors Tanaka, Kiho, Kim, Youry, Roche, Michael, Lewin, Sharon R.
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc 01.10.2022
Subjects
Antiretroviral therapy
Cell death
Clinical trials
HIV
HIV cure strategies
HIV reservoir
Human immunodeficiency virus
immune checkpoint blocker
immunotherapy
Latency
latency reversal
Latent infection
Viruses
Online AccessGet full text

Cover

More Information
Summary:One strategy to eliminate latently infected cells that persist in people with HIV on antiretroviral therapy is to activate virus transcription and virus production to induce virus or immune‐mediated cell death. This is called latency reversal. Despite clear activity of multiple latency reversal agents in vitro, clinical trials of latency‐reversing agents have not shown significant reduction in latently infected cells. We review new insights into the biology of HIV latency and discuss novel approaches to enhance the efficacy of latency reversal agents.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
ISSN:0047-2565
1600-0684
DOI:10.1111/jmp.12613